An assessment of levetiracetam as an anti-epileptic drug

Bibliography

• BIALER M, JOHANNESSEN SI, KUPFERBERG HJ et al.: Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. (1999) 34:1–41.
   PubMed Web of Science ®Google Scholar
• ••Source of information about drugs in development forepilepsy.
   Google Scholar
• WALKER MC, PATSALOS PN: Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol. Ther. (1995) 67:351–384.
   PubMed Web of Science ®Google Scholar
• LOSCHER W, RICHTER A: Piracetam and levetiracetam,two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia. Eur. J. Pharmacol. (2000) 391:251–254.
   PubMed Web of Science ®Google Scholar
• NOYER M, GILLARD M, MATAGNE A et al.: The novel antiepileptic drug levetiracetam (UCB L059) appears to act via a specific binding site in CNS membranes. Eur.J. Pharmacol. (1995) 286:137–146.
   PubMed Web of Science ®Google Scholar
• GOWER AJ, NOYER M, VERLOES R et al.: UCB L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol. (1992) 222:193–203.
   PubMed Web of Science ®Google Scholar
• LOSCHER W, HONACK D: Profile of UCB L059, a novel anticonvulsant drug, in models of partial and general-ized epilepsy in mice and rats. Eur. J. Pharmacol (1993) 232:147–158.
   PubMed Web of Science ®Google Scholar
• MARGINEANU D, WULFERT E: UCB L059, a novel anticonvulsant, reduces bicuculline-induced neuronal hyperexcitability, possibly through Ca-dependent mechanisms. Pharmacol. Res. (1995) 31:347.
   PubMed Web of Science ®Google Scholar
• SILLS GJ, LEACH JR, FRASER CM, FORREST G, PATSALOS PN, BRODIE MJ: Neurochemical actions of the novel anticonvulsant levetiracetam in mouse brain. Eur. J. Pharmacol. (1997) 325:35–40.
   PubMed Web of Science ®Google Scholar
• LOSCHER W, HONACK D, BLOMS-FUNKE P: The novelantiepileptic drug levetiracetam (UCB L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata. Brain Res. (1996) 735 (Suppl. 2):208–216.
   Google Scholar
• GOWER AJ, HIRSCH E, BOEHRER A, NOYER M, MARESCAUX C: Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. (1995) 22:207–213.
   PubMed Web of Science ®Google Scholar
• LOSCHER W, HONACK D, RUNDFELDT C: Antiepilepto-genic effects of the novel anticonvulsant levetiracetam (UCB L059) in the kindling model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. (1998) 284:474–479.
   PubMed Web of Science ®Google Scholar
• LOSCHER W, REISSMULLER E, EBERT U: Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats. Epilepsy Res. (2000) 40:63–77.
   PubMed Web of Science ®Google Scholar
• KLITGAARD H, MATAGNE A, GOBERT J et al.: Evidencefor a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol (1998) 353:191–206.
   PubMed Web of Science ®Google Scholar
• PATSALOS PN: Pharmacokinetic profile of leveti-racetam: towards ideal characteristics. Pharmacol. Ther. (2000) 85:77–85.
   PubMed Web of Science ®Google Scholar
• DOHENY HC, RATNARAJ N, WHITTINGTON MA et al.: Blood and cerebrospinal fluid pharmacokinetics. Epilepsy Res. (1999) 34:161–168.
   PubMed Web of Science ®Google Scholar
• RATNARAJ N, DOHENY HC, PATSALOS PN: Kinetics of levetiracetame in rat blood and cerebrospinal fluid. Epilepsia (1995) 36\(Suppl. 3):538.
   Google Scholar
• NICOLAS JM, COLLART P, GERIN B et al.: In vitro evalua-tion of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug. Metab. Dispos. (1999) 27:250–254.
   PubMed Web of Science ®Google Scholar
• PATSALOS PN: Phenobarbitone to gabapentin: a guide to 82 years of anti-epileptic drug pharmacokinetic interactions. Seizure (1994) 3:163–170.
   PubMedGoogle Scholar
• SHARIEF MK, SINGH P, SANDER JWAS, PATSALOS PN, SHORVON SD: Efficacy and tolerability study of UCB L059 in patients with refractory epilepsy. J. Epilepsy (1996) 9:106–112.
   Google Scholar
• SZABO GK, PERCHALSKI RJ, BROWNE DG et al.: Alterna-tive to mass spectrometry for quantitation of stable isotopes: high performance liquid chromatography with conventional ultraviolet detection. In: Pharmaco-chemistry Library: Vol 26: Stable Isotopes in Pharmaceutical Research. Browne TR (Ed.), Elsevier Science, Amsterdam (1997) :127–140.
   Google Scholar
• BROWNE TR, SZABO GK, LEPPIK IE et al.: Absence ofpharmacokinetic drug interaction of levetiracetam with phenytoin in patients with epilepsy determined by new technique. J. Clin. Pharmacol (2000) 40:1–6.
   Web of Science ®Google Scholar
• GIULIANO RA, HIERSEMENSEL R, BALTES E, JOHNSCHERG, JANIK F, WEBER W: Influence of a new antiepileptic drug (Levetiracetam, UCB L059) on the pharmacoki-netics and pharmacodynamics of oral contraceptives. Epilepsia (1996) 37 (Suppl. 4):90 (Abstract).
   Google Scholar
• BETTS A, WAEGEMANS T, CRAWFORD P: Multicentre, double-blind, randomised, parallel group study was conducted to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure (2000) 9:80–87.
   PubMed Web of Science ®Google Scholar
• ••Only Phase III clinical trial published in full so far.
   Google Scholar
• BEN-MENACHEM E, FORTPLED C, FALTER U etal: Evalua-tion of the efficacy and tolerability of levetiracetam (LEV) monotherapy in epileptic patients with complex partial onset seizures. Epilepsia (1999) 40\(Suppl. 2)249 (Abstract).
   Google Scholar
• HANON S, KLITGAARD H: Levetiracetam reveals neuroprotective properties in an animal model of transient focal ischemia. 8th International Symposium on Pharmacology of Cerebral Ischaemia. Marburg, Germany (July 1999).
   Google Scholar
• LAMBERTY Y, GOEMAERE J, KLITGAARD H: Cognitive performance is unaltered by levetiracetam (UCB L059) in the pilocarpine model of chronic epilepsy. Epilepsia (1998) 39 (Suppl. 2):85 (Abstract).
   Google Scholar
• LAMBERTY Y, KLITGAARD H: Lack of negative impact on cognitive function differentiates levetiracetam (UCB L059) from other antiepileptic drugs. Epilepsia (1998) 39 (Suppl. 6):45 (Abstract).
   Google Scholar
• CHEVALIER Y, GRANT R, SANDER JWAS et al.: Twelve week add-on, increasing dose (1,000-4,000 mg/day) multicenter pilot study of ucb L059 in epileptic patients. Epilepsia (1995) 36 (Suppl. 3):S153.
   Google Scholar
• NEYENS LG, ALPHERTS WC, ALDENKAMP AP: Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog. Neuropsychopharmacol. Psychiatry (1995) 19:411–419.
   PubMed Web of Science ®Google Scholar
• JAIN KK: Neuroprotection. Jain PharmaBiotech, Basel, Switzerland (2000).
   Google Scholar
• ROGAWSKI MA, LE DQ, UYAKUL D et al.: Anticonvulsant efficacy of ADCI (5-aminocarbony1-10,11-dihydro-51-1-dibenzok,c0cyclohepten-5,10-imine) after acute and chronic dosing in mice. Epilepsia (1995) 36:566–571.
   PubMed Web of Science ®Google Scholar
• SIGEL E, BAUR R, NETZER R et al: The antiepileptic drug AWD 131-138 stimulates different recombinant isoforms of the rat GABA(A) receptor through the benzodiazepine binding site. Neurosci. Lett. (1998) 245:85–88.
   PubMed Web of Science ®Google Scholar
• KOZAK A, DOLINA S, KAMBURG S et al: DP-VPA, a novelprodrug of VPA has enhanced protective effect in genetically epilepsy-prone mice. Soc. NeuroscL Abstr. (1997) 23 (Part 2):2163.
   Google Scholar
• MONAGHAN EP, NAVALTA LA, SHUM L et al.: Initialhuman experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia (1997) 38:1026–1031.
   PubMed Web of Science ®Google Scholar
• BIBER A, DIENEL A: Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. (1996) 34:6–11.
   PubMed Web of Science ®Google Scholar
• JONES FA, DAVIES JA: The anticonvulsant effects of the enantiomers of losigamone. Br. J. Pharmacol (1999) 128:1223–1228.
   PubMed Web of Science ®Google Scholar
• BRYANS JS, WUSTROW DJ: 3-substituted GABA analogs with central nervous system activity: a review. Med. Res. Rev. (1999) 19:149–177.
   PubMed Web of Science ®Google Scholar
• RUNDFELDT C: The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur. J. Pharmacol. (1997) 336:243–249.
   PubMed Web of Science ®Google Scholar
• BLOTNIK S, BERGMAN F, BIALER M: The disposition of valproyl glycinamide and valproyl glycine in rats. Pharmacol. Res. (1997) 14:873–878.
   Web of Science ®Google Scholar
• VAN RIJCKEVORSELK K, DEBRABANDERE L, DEBERDT W: Evaluation of the efficacy and tolerability of UCB L059 in refractory epileptic patients with complex partial seizures: A 12 week, single blind, add-on, rising dose study. Epilepsia (1996) 37 (Suppl. 5):169.
   Google Scholar
• KASTELEIJN-NOLST TRENITÉ DGA, MARESCAUX C et al.: Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res. (1996) 25:225–230.
   PubMed Web of Science ®Google Scholar
• DREIFUSS F, CEREGHINO J, DEBRABANDERE L et al.: Multicenter, double-blind, placebo-controlled trial of ucbL059 (500 mg b.i.d. and 1500 mg bid.) as add-on therapy in patients with refractory partial epilepsy. Epilepsia (1996) 37 (Suppl. 5):204.
   Google Scholar
• CAMERON N, PENOVICH PE, RITTER FJ et al: Open-label study of UCB L059 as add-on therapy in refractory partial epilepsy. Epilepsia (1996) 37\(Suppl. 5):169.
   Google Scholar
• CREECH J, ABOU-KHALIL BW, FAKHOURY T et al.: Leveti-racetam in intractable partial epilepsy: efficacy of add-on therapy and patient retention. Epilepsia (1999) 40 (Suppl. 7):148 (Abstract 2.259).
   Google Scholar
• MAURIZIS JC, MADELMONT JC, RAPP M etal.: Disposition and metabolism of 2,6-dimethylbenzamide n-(5-methyl-3-isoxazoly0 (D2916) in male and female rats. Drug Metab. Dispos. (1997) 25:33–39.
   Google Scholar
• UCB SA Pharma, Brussels, Belgium. Data on file. Quoted by Betts et al. (2000).
   Google Scholar